eMediWrite

AUGUST 24, 2023

Medical publications are often highly valued by doctors because they are essential to their professional practice and continuous education. The main source of new and up-to-date information on medical research, clinical trials, treatment recommendations, and developments in medical science is medical journals.

Doctors 52

Doctors Physicians Medical Education 52

Pharmaceutical Technology

NOVEMBER 2, 2022

Acting as a go-between for pharma and physicians, medical science liaisons (MSLs) are responsible for communicating necessary information about new medicines to healthcare professionals and key opinion leaders (KOLs). As with many aspects of the medical world, they are now shifting online. Expanding horizons.

Medical 52

Medical Medicine Pharma Networking 52

MedTechVets

NOVEMBER 19, 2020

The issue that often arises for veterans is the lack of a strong professional network, required licenses for a job, and no clear pathway from the military to a mid-to-high-skill civilian job like medical sales. You’ll need to talk to doctors, medical providers, pharmacists, doctors, and nurses.

Medical sales 52

Medical sales Medical Sales Training 52

PM360

NOVEMBER 29, 2022

Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. They are no longer “just” educating and informing doctors but helping to accelerate medical science innovation.

Medical science 95

Medical science Medical Customer Relationship Management Doctors 95

PM360

SEPTEMBER 15, 2022

The pandemic has also disrupted how HCPs interact with their colleagues and pharma in sharing information. Where once pharma relied on reps and medical science liaisons (MSLs) to engage clinicians, many digital interactions, such as video conferencing, have replaced the need for in-person meetings.

Education 52

Education Media Medical Physicians 52

PM360

NOVEMBER 21, 2022

When Marc’s doctors discovered he had a rare liver condition, it almost felt like a relief. Combined with the incentives provided by the Orphan Drug Act, a powerful dynamic is at play, ever further pushing the limits of what medical science can achieve. At least his enemy now had a name. Understanding Rare Disease Communities.

Patients 52

Patients Medicine Biopharma Media 52